Medical Services Provided in Inpatient Drug Rehab Facilities

Inpatient drug rehab facilities deliver a range of structured medical services that go far beyond basic housing and counseling support. This page documents the clinical service categories provided within residential treatment settings, the regulatory frameworks governing those services, and the organizational boundaries that separate inpatient medical care from outpatient or ambulatory alternatives. The scope encompasses both physical health and psychiatric services, reflecting the established clinical consensus that substance use disorders involve neurobiological, psychological, and physiological dimensions that require coordinated medical attention.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps (non-advisory)
• Reference table or matrix

Definition and scope

Inpatient drug rehab, in regulatory and clinical terminology, refers to residential treatment programs in which patients live on-site and receive 24-hour medically supervised care. The Substance Abuse and Mental Health Services Administration (SAMHSA) defines residential substance use disorder treatment as a structured living environment where clinical services are integrated into daily programming (SAMHSA Treatment Improvement Protocol TIP 63).

Medical services in this context span a continuum that begins at intake and extends through discharge planning. The American Society of Addiction Medicine (ASAM) Patient Placement Criteria — the dominant clinical framework in the United States — organizes inpatient services across Level 3 (Residential) and Level 4 (Medically Managed Intensive Inpatient) care designations. Level 4 settings are typically hospital-based, providing physician-directed services 24 hours per day (ASAM Criteria, Third Edition). Level 3 settings offer varying degrees of medical staffing, from clinician-monitored to medically monitored environments.

The scope of medical services provided in inpatient rehab is shaped by three overlapping frameworks: state licensure requirements, federal Conditions of Participation for facilities receiving Medicare or Medicaid reimbursement, and voluntary accreditation standards set by bodies such as The Joint Commission and the Commission on Accreditation of Rehabilitation Facilities (CARF). For a broader orientation to levels of care and ASAM criteria, that framework is documented separately.

Core mechanics or structure

Medical services within inpatient facilities are organized into discrete phases that follow a patient's trajectory from admission through discharge.

Medical intake and assessment. Upon admission, a licensed medical professional — typically a physician or nurse practitioner — conducts a comprehensive physical examination. This assessment documents current vital signs, identifies signs of acute intoxication or withdrawal, screens for infectious disease (including HIV, hepatitis B, and hepatitis C), and establishes baseline lab values. SAMHSA's Treatment Improvement Protocol TIP 45 identifies the comprehensive assessment as a foundational requirement for treatment matching (TIP 45).

Medical detoxification. Detox services in drug rehab constitute the most acutely medical phase of inpatient care. Withdrawal management protocols are substance-specific: alcohol withdrawal is monitored using validated tools such as the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar), which scores 10 symptom categories on a scale up to 67 points, with scores above 15 indicating severe withdrawal risk. Opioid withdrawal is commonly tracked using the Clinical Opiate Withdrawal Scale (COWS). Benzodiazepine tapering protocols are used to prevent seizures during benzodiazepine addiction treatment.

Medication-Assisted Treatment (MAT) administration. Many inpatient facilities administer FDA-approved medications for opioid use disorder (MOUD). These include buprenorphine (Suboxone), methadone administered under federal opioid treatment program (OTP) regulations, and extended-release naltrexone (Vivitrol). A full overview of medication-assisted treatment is documented separately. The Drug Enforcement Administration (DEA) governs prescribing authority for Schedule II–IV substances used in addiction treatment under the Controlled Substances Act (21 U.S.C. § 801 et seq.).

Psychiatric and co-occurring disorder services. Inpatient facilities that are licensed to treat co-occurring disorders and dual diagnosis maintain psychiatric staff capable of diagnosing and managing conditions such as major depressive disorder, bipolar disorder, PTSD, and anxiety disorders concurrent with substance use disorders. The National Survey on Drug Use and Health (NSDUH) consistently documents that more than 9 million adults in the United States experience both a mental illness and a substance use disorder in a given year (SAMHSA NSDUH 2022).

Chronic disease management. Patients in inpatient rehab frequently present with comorbid physical conditions including hypertension, diabetes, hepatic disease, and infectious diseases directly associated with substance use. Medical staff manage these conditions throughout the inpatient stay, coordinating with specialists when indicated.

Discharge planning and continuing care linkage. Medical discharge planning is a required service component under Joint Commission standards for behavioral health accreditation. Discharge plans document medication prescriptions, follow-up appointments, and referrals to step-down levels of care.

Causal relationships or drivers

The breadth of medical services in inpatient settings is driven by the physiological complexity of substance dependence. Chronic use of substances including opioids, alcohol, benzodiazepines, and stimulants produces neuroadaptive changes that create medically significant withdrawal syndromes upon cessation. Alcohol withdrawal, for example, can progress to delirium tremens in approximately 3–5% of untreated patients, a condition carrying a mortality rate of up to 15% without medical management, according to data cited in the National Institute on Alcohol Abuse and Alcoholism (NIAAA) alcohol alert series (NIAAA Alcohol Alert No. 72).

High rates of infectious disease among people who inject drugs — including HIV and hepatitis C — create additional medical service demand. The Centers for Disease Control and Prevention (CDC) estimates that approximately 70% of new hepatitis C infections in the United States are attributable to injection drug use (CDC Viral Hepatitis Statistics).

Regulatory pressure also drives service expansion. The Affordable Care Act's classification of substance use disorder treatment as an Essential Health Benefit under 42 U.S.C. § 18022 obligates insurers to cover medically necessary inpatient services, creating financial infrastructure that enables facilities to staff medical personnel. Details on Affordable Care Act rehab requirements are covered in the corresponding reference page.

Classification boundaries

Not all inpatient facilities provide the same service depth. The ASAM criteria establish meaningful distinctions:

• Level 3.1 (Clinically Managed Low-Intensity Residential): Primarily social and counseling support; medical staff available but not continuously on-site.
• Level 3.5 (Clinically Managed High-Intensity Residential): 24-hour supervision; nursing available; physician on call. Appropriate for patients with moderate-severity withdrawal.
• Level 3.7 (Medically Monitored Intensive Inpatient): Nursing present 24 hours; physician available within 8 hours. This level manages medically complex patients who do not require acute hospital services.
• Level 4.0 (Medically Managed Intensive Inpatient): Physician on-site 24 hours; hospital-based or equivalent. Manages severe or life-threatening withdrawal and complex comorbidities.

These classifications carry direct implications for drug rehab program types that are documented in the corresponding reference.

Facilities operating as Opioid Treatment Programs (OTPs) under 42 C.F.R. Part 8 are governed by additional DEA registration and SAMHSA certification requirements, distinguishing them from general residential programs that do not administer methadone. 42 C.F.R. Part 8 was amended effective February 23, 2026; facilities must verify current OTP certification and operational requirements against the amended regulatory text, as provisions governing OTP certification standards, staffing, and operational requirements may differ from prior versions. Current regulatory text is available at eCFR, 42 CFR Part 8.

Tradeoffs and tensions

Medical intensity vs. therapeutic environment. High medical staffing ratios and clinical monitoring can create environments that resemble acute hospital care more than therapeutic community models. Research on therapeutic community outcomes, including work published through the National Institute on Drug Abuse (NIDA), suggests that peer-based social structures contribute to long-term recovery, a factor that heavily medicalized environments may inadvertently suppress.

Medication-Assisted Treatment adoption. Federal policy, including the 2023 elimination of the DEA X-waiver requirement under the Mainstreaming Addiction Treatment (MAT) Act provision of the Consolidated Appropriations Act of 2023, expanded prescribing authority for buprenorphine. Despite this, a proportion of residential programs continue to restrict or prohibit MAT, often citing program philosophy rather than clinical evidence. NIDA has documented that medications for opioid use disorder reduce mortality and improve treatment retention (NIDA Effective Treatments for Opioid Addiction).

Length of stay and insurance authorization. Medical necessity determinations by insurers frequently conflict with clinically indicated length-of-stay recommendations. The ASAM criteria do not set fixed durations, emphasizing individualized assessment, while utilization management practices may limit stays to standardized benchmarks. This tension is examined further in the drug rehab length of stay reference.

Privacy regulations. 42 C.F.R. Part 2 (Confidentiality of Substance Use Disorder Patient Records) imposes stricter confidentiality protections on substance use disorder records than HIPAA alone, complicating integrated care coordination between addiction medicine providers and primary care or specialty physicians. HIPAA confidentiality in rehab covers these regulatory distinctions in detail.

Common misconceptions

Misconception: Inpatient rehab is medically equivalent to a hospital admission.
Correction: Level 3 residential settings are not licensed as acute care hospitals and do not provide the surgical, radiological, or intensive care services associated with hospital admission. Level 4 medically managed settings approach hospital-level addiction care, but even these maintain a distinct clinical scope.

Misconception: Medical detox and rehabilitation are the same service.
Correction: Detoxification addresses acute physiological stabilization, typically lasting 3–10 days depending on the substance. Rehabilitation encompasses the broader therapeutic, psychiatric, and medical programming that follows stabilization. A patient who completes detox has not completed rehabilitation.

Misconception: Facilities that do not administer medications are not providing medical services.
Correction: Medical services include assessment, monitoring, infectious disease screening, chronic disease management, psychiatric evaluation, and discharge planning — none of which require MAT administration. The absence of MAT reflects a program policy choice, not an absence of medical infrastructure.

Misconception: All residential programs must be accredited by The Joint Commission.
Correction: Joint Commission accreditation is voluntary, not federally mandated. State licensure is the minimum legal requirement. Accreditation by The Joint Commission or CARF, while indicative of adherence to defined quality standards, is not universally required for program operation. Rehab accreditation and licensing details these distinctions.

Checklist or steps (non-advisory)

The following sequence identifies the standard medical service touchpoints within an inpatient drug rehab episode of care. This is a structural reference documenting common practice, not a clinical protocol.

1. Pre-admission screening — Telephone or in-person intake assessment to establish medical eligibility, primary substance, and acuity level.
2. Medical intake examination — Physical examination, vital sign documentation, and medical history collection by licensed clinical staff.
3. Laboratory evaluation — Blood panel (CBC, CMP, liver function tests), urine drug screen, communicable disease testing (HIV, hepatitis B surface antigen, hepatitis C antibody).
4. Withdrawal risk stratification — Administration of validated instruments (CIWA-Ar for alcohol, COWS for opioids) to determine monitoring intensity.
5. Medically supervised withdrawal management — Substance-specific protocols with scheduled medication administration and symptom monitoring intervals.
6. Psychiatric evaluation — Structured diagnostic interview to identify co-occurring mental health disorders; medication management initiated if indicated.
7. Chronic disease stabilization — Continuation or initiation of treatment for hypertension, diabetes, hepatic disease, or other identified conditions.
8. MAT initiation (if applicable) — Induction onto FDA-approved pharmacotherapy under licensed prescriber supervision, per DEA and facility protocols.
9. Ongoing medical monitoring — Daily nursing assessment, medication administration records, and progress note documentation throughout residential stay.
10. Discharge medical planning — Prescription documentation, specialist referral coordination, and warm handoff to continuing care providers.

Reference table or matrix

References

• SAMHSA Treatment Improvement Protocol TIP 45: Detoxification and Substance Abuse Treatment
• SAMHSA Treatment Improvement Protocol TIP 63: Medications for Opioid Use Disorder
• SAMHSA 2022 National Survey on Drug Use and Health (NSDUH)
• American Society of Addiction Medicine (ASAM) Criteria, Third Edition
• National Institute on Alcohol Abuse and Alcoholism (NIAAA) Alcohol Alert No. 72
• National Institute on Drug Abuse (NIDA): Effective Treatments for Opioid Addiction
• Centers for Disease Control and Prevention: Viral Hepatitis Statistics and Surveillance
• [Drug